(Q38178093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Evaluation of tumor size response metrics to predict survival in oncology clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Francois Mercier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

L Claret

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

13 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

386-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

Industry and regulatory performance in 2012: a year in review

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Models of excellence: improving oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Model-based drug development in oncology: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Joint inference for nonlinear mixed-effects models and time to event at the presence of missing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Modeling NSCLC progression: recent advances and opportunities available

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Resampling phase III data to assess phase II trial designs and endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Tumor burden modeling versus progression-free survival for phase II decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Estimation of renal cell carcinoma treatment effects from disease progression modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

Clinical Approval Success Rates for Investigational Cancer Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

7 January 2021

How to improve R&D productivity: the pharmaceutical industry's grand challenge

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

7 January 2021

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

7 January 2021

Measuring response in a post-RECIST world: from black and white to shades of grey

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

7 January 2021

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.4

7 January 2021

Identifiers

DOI

10.1038/CLPT.2014.4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24419563%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference